戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 anges, including activation of genes such as atrial natriuretic factor.
2 tricular output, and possibly high levels of atrial natriuretic factor.
3 icular expression of the load-sensitive gene atrial natriuretic factor.
4               They also express the gene for atrial natriuretic factor.
5 e an 8-fold increase in ventricular mRNA for atrial natriuretic factor.
6 osin heavy chain, myosin light chain 2v, and atrial natriuretic factor.
7 nduction of fetal genes such as betaMyHC and atrial natriuretic factor.
8 d expression of the hypertrophic marker gene atrial natriuretic factor.
9 lmonary congestion and had reduced levels of atrial natriuretic factor.
10 ricles expressed beta-myosin heavy chain and atrial natriuretic factor.
11 y reduced ET-1- and PE-induced expression of atrial natriuretic factor.
12 e, sarcomeric organization, and induction of atrial natriuretic factor.
13                              CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elic
14 ed in the morphants including an increase in atrial natriuretic factor, a hallmark for cardiac hypert
15  we find that fluorescence from Topaz-tagged atrial natriuretic factor, a peptidergic vesicle pH indi
16  LV fibrosis, and expression of fetal genes (atrial natriuretic factor, alpha-skeletal muscle actin,
17 spholamban restored the expression levels of atrial natriuretic factor and alpha-skeletal actin mRNA
18 function and decreased cardiac expression of atrial natriuretic factor and alpha-skeletal actin mRNA.
19 n neonatal hearts, ventricular expression of atrial natriuretic factor and alpha-skeletal actin was m
20 ore, mRNA expressions of the embryonic genes atrial natriuretic factor and alpha-skeletal actin were
21 arkers of hypertrophy, alpha-skeletal actin, atrial natriuretic factor and beta-MyHC, were upregulate
22 ell area, protein content, and the mRNAs for atrial natriuretic factor and beta-MyHC.
23 ificantly increased heart/body weight ratio, atrial natriuretic factor and beta-myosin heavy chain mR
24  hearts demonstrate significant induction of atrial natriuretic factor and beta-myosin heavy chain tr
25 e cross-sectional areas, hypertrophy markers atrial natriuretic factor and beta-myosin heavy chain).
26 ition, two cardiac hypertrophy marker genes, atrial natriuretic factor and beta-myosin heavy chain, w
27 en synthesis and hypertrophy markers such as atrial natriuretic factor and beta-myosin heavy chain.
28 enuated expression of the trabecular markers atrial natriuretic factor and bone morphogenic protein 1
29 el pathways associated with up-regulation of atrial natriuretic factor and brain natriuretic peptide
30 ist-induced expression of the embryonic gene atrial natriuretic factor and enlargement of cardiomyocy
31 f the expression of various genes, including atrial natriuretic factor and Ifi204 (encoding p204).
32 d and endothelin-1-mediated induction of the atrial natriuretic factor and myosin light chain-2 genes
33      It prevented PE-stimulated increases in atrial natriuretic factor and myosin light chain-2 mRNA
34  activated reporter expression from both the atrial natriuretic factor and myosin light chain-2 ventr
35 trophy, increased expression of fetal genes (atrial natriuretic factor and skeletal alpha-actin), dec
36 accompanied by enhanced expression of prepro-atrial natriuretic factor and skeletal alpha-actin.
37 cardiac expression of HF marker genes (GRK2, atrial natriuretic factor, and beta-myosin heavy chain).
38 yosin heavy chain, cardiac troponin I and T, atrial natriuretic factor, and cardiac transcription fac
39 ncrease in cell size, elevated expression of atrial natriuretic factor, and induction of sarcomere or
40 RNA expression of brain natriuretic peptide, atrial natriuretic factor, and renin were significantly
41 m cardiac enzymes, plasma catecholamines and atrial natriuretic factor, and SaO2.
42  i.e. those for c-Fos, skeletal alpha-actin, atrial natriuretic factor, and the alpha3-subunit of Na+
43 19%), secreted more apoB, and expressed less atrial natriuretic factor (ANF) and brain natriuretic pe
44 5 haploinsufficiency also markedly decreased atrial natriuretic factor (ANF) and connexin 40 (cx40) t
45 function, its synergism with partners at the atrial natriuretic factor (ANF) and connexin-40 (Cx40) p
46 are markers of cardiac hypertrophy including atrial natriuretic factor (ANF) and myosin light chain-2
47  (GSK3beta) is critical for transcription of atrial natriuretic factor (ANF) by beta-adrenergic recep
48          The promoter-enhancer region of the atrial natriuretic factor (ANF) contains several putativ
49 induced increases in NADPH oxidase activity, atrial natriuretic factor (ANF) expression, and cardiac
50 promoter/luciferase reporter genes, increase atrial natriuretic factor (ANF) expression, and promote
51 terized by transcriptional activation of the atrial natriuretic factor (ANF) gene and enlargement (hy
52          IL-18 has also been shown to induce atrial natriuretic factor (ANF) gene expression in adult
53                                          The atrial natriuretic factor (ANF) gene is initially expres
54 otic expression screen for activators of the atrial natriuretic factor (ANF) gene, a cardiac-specific
55                               In the cardiac atrial natriuretic factor (ANF) gene, a promoter-proxima
56 its DNA binding sites in the promoter of the atrial natriuretic factor (ANF) gene, an in vivo target
57  immediate early genes, and up-regulates the atrial natriuretic factor (ANF) gene, but does not affec
58 h considerable evidence indicates a role for atrial natriuretic factor (ANF) in renal salt regulation
59                                              Atrial natriuretic factor (ANF) inhibits proliferation i
60                                              Atrial natriuretic factor (ANF) is abundantly expressed
61   In contrast, while MnTMPyP inhibited basal atrial natriuretic factor (ANF) mRNA expression, the str
62      Phenylephrine-induced activation of the atrial natriuretic factor (ANF) promoter (measured by th
63 ed protein content, [3H] leucine uptake, and atrial natriuretic factor (ANF) promoter activity.
64  containing c-Jun and with the cardiomyocyte atrial natriuretic factor (anf) promoter and the cardiac
65                      We report here that the atrial natriuretic factor (ANF) promoter is a target of
66 can induce reporter gene expression from the atrial natriuretic factor (ANF) promoter, a genetic mark
67 vation of cardiac gene promoters such as the atrial natriuretic factor (ANF) promoter.
68 ignificance of this interaction, we used the atrial natriuretic factor (ANF) promoter.
69          Both inhibitors markedly attenuated atrial natriuretic factor (ANF) reporter gene expression
70                 We examined the mechanism of atrial natriuretic factor (ANF) transcription by isoprot
71 bx20, activates a cardiac-specific promoter (atrial natriuretic factor (ANF)) alone and synergistical
72  messenger ribonucleic acid (mRNA) levels of atrial natriuretic factor (ANF), beta-myosin heavy chain
73                                These include atrial natriuretic factor (ANF), beta-myosin heavy chain
74 embryonic hearts expressed similar levels of atrial natriuretic factor (ANF), brain natriuretic pepti
75 cular expression of several genes, including atrial natriuretic factor (ANF), has been documented in
76  Zic3(null/y) embryonic stem cells including atrial natriuretic factor (ANF), Nkx2.5 and Tbx5.
77 perated with c-Raf to increase expression of atrial natriuretic factor (ANF), whereas N17Rac1 inhibit
78 tivator of p38, stimulated the expression of atrial natriuretic factor (ANF), which is a genetic mark
79                                We found that atrial natriuretic factor (ANF), which is normally expre
80 , and reexpression of the embryonic gene for atrial natriuretic factor (ANF).
81 des expression of the cardiac-specific gene, atrial natriuretic factor (ANF).
82 ion of cardiac-specific genes, including the atrial natriuretic factor (ANF).
83 ve mRNA levels of the hypertrophy-associated atrial natriuretic factor (ANF, 2.1-fold) and skeletal a
84 nduced expression of two hypertrophic genes (atrial natriuretic factor [ANF] and c-myc) and also enha
85 al hydrolysis of ligand (125I-labeled native atrial natriuretic factor, ANF1-28), and receptor recycl
86 pregulation of hypertrophy markers including atrial natriuretic factor, beta-MHC, and GATA4; and acti
87 onic and contractile protein genes including atrial natriuretic factor, beta-myosin heavy chain, and
88 expression of the hypertrophic marker genes, atrial natriuretic factor, brain natriuretic peptide, an
89 rization ability inhibited the activation of atrial natriuretic factor by wild-type CSX/NKX2.5.
90    We investigated the potential of a C-type atrial natriuretic factor (C-ANF) to image developing pl
91  of mRNAs for fetal type myosin heavy chain, atrial natriuretic factor, c-fos, transforming growth fa
92 ently, we reported the (64)Cu-labeled C-type atrial natriuretic factor (CANF) fragment for detecting
93 pressed genes including cardiac alpha actin, atrial natriuretic factor, cardiac myosin heavy chain al
94 o well-known markers of cardiac hypertrophy (atrial natriuretic factor, CARP, and beta-myosin heavy c
95 , overexpression of NF-kappaB itself induced atrial natriuretic factor expression and cardiomyocyte e
96 heart-to-body weight ratios with ventricular atrial natriuretic factor expression denoting myocardial
97 ment, sarcomeric organization, and increased atrial natriuretic factor expression in association with
98 P79 attenuated cardiomyocyte hypertrophy and atrial natriuretic factor expression in response to angi
99                              Hypertrophy and atrial natriuretic factor expression induced by angioten
100                                              Atrial natriuretic factor expression was approximately 6
101 ng Ras-induced myofibrillar organization and atrial natriuretic factor expression was only minimally
102 ha(1B)AR-induced hypertrophy and ventricular atrial natriuretic factor expression were significantly
103 ction, which induced myocyte hypertrophy and atrial natriuretic factor expression, protected against
104 t, cardiomyocyte diameter, and inhibition of atrial natriuretic factor expression.
105 hanced sarcomeric organization, and elevated atrial natriuretic factor expression.
106 ficant reduction in NF-kappaB activation and atrial natriuretic factor expression.
107 ed protein synthesis, cell surface area, and atrial natriuretic factor expression.
108                    In contrast, secretion of atrial natriuretic factor from ventricular myocytes was
109  MAPK cascade, and (c) induction of c-fos or atrial natriuretic factor gene occurred partly through t
110 ocardin A transactivated the promoter of the atrial natriuretic factor gene through the serum respons
111 ssion of cardiac-specific promoters from the atrial natriuretic factor gene, the b-type natriuretic p
112 n, whereas it did not increase expression of atrial natriuretic factor gene.
113 ithin the proximal promoter -242 site of the atrial natriuretic factor gene.
114 ytosis were developed by expressing a prepro-atrial natriuretic factor-green fluorescent protein fusi
115 ganization, increased cell size, and induced atrial natriuretic factor in cardiomyocytes plated on th
116 els of cardiac hypertrophy and expression of atrial natriuretic factor in Mekk1(-/-) animals, which s
117 s-sectional area, and hypertrophy-associated atrial natriuretic factor induction following pressure o
118 days) did not affect the trophic response or atrial natriuretic factor induction to pressure overload
119 c mass, myocyte size, hypertrophy-associated atrial natriuretic factor induction, and c-Jun N-termina
120    The C3 treatment inhibited Ang II-induced atrial natriuretic factor induction, whereas it had no e
121 r studies of singular prevention strategies (atrial natriuretic factor, loop diuretics, dopamine, man
122 iferase gene expression but no activation of atrial natriuretic factor-luciferase gene expression.
123  accumulation, coincident with activation of atrial natriuretic factor-luciferase gene expression.
124 O mice shows a dramatic up-regulation of the atrial natriuretic factor message, a well-established bi
125  ET-1 also induced a significant increase in atrial natriuretic factor mRNA expression as well as in
126 here were no significant changes in IGF-1 or atrial natriuretic factor mRNA levels in response to GH
127    There was also an increase in ventricular atrial natriuretic factor mRNA levels, demonstrating act
128 ttenuate increased ventricular expression of atrial natriuretic factor mRNA.
129 n reaction, we measured transcript levels of atrial natriuretic factor, myosin heavy chain-alpha and
130 with the rat, none of these agents increased atrial natriuretic factor or beta-MyHC mRNAs.
131 mg/mm; p<0.001) and reduced LV expression of atrial natriuretic factor (p<0.05), alpha-skeletal muscl
132 hy like: alpha- and beta-myosin heavy chain, atrial natriuretic factor, phospholamban, and sarcoplasm
133 in cell size, sarcomeric reorganization, and atrial natriuretic factor production were remarkably att
134 ponse when assessed by protein synthesis and atrial natriuretic factor production, a marker gene of h
135                              Serum increased atrial natriuretic factor promoter activity and cell siz
136                                    We tested atrial natriuretic factor promoter activity as a positiv
137 as co-transfected with SRF, but it repressed atrial natriuretic factor promoter activity, which was s
138 P-TF2dependent synergistic activation of the atrial natriuretic factor promoter by both GATA4 and the
139 educed the capability of SRF to activate the atrial natriuretic factor promoter that contains the ser
140 that CARP inhibits Nkx2.5 transactivation of atrial natriuretic factor promoter.
141  novel VEGF-B167 transgene controlled by the atrial natriuretic factor promoter.
142 hat Tip60 and SRF cooperatively activate the atrial natriuretic factor promoter.
143 onal responsiveness of ELK-1, GATA4, and the atrial natriuretic factor promoter.
144 arcomeric units and in the expression of the atrial natriuretic factor protein.
145  and of the other retinal guanylate cyclase, atrial natriuretic factor-receptor guanylate cyclase.
146 onomous accumulation of the endocytic tracer atrial natriuretic factor-red fluorescent protein at ear
147  that TBX5 activates the transcription of an atrial natriuretic factor reporter construct and this ef
148 ons of the genes of skeletal alpha-actin and atrial natriuretic factor, repression of the gene of the
149 omains inhibited the adrenergically mediated atrial natriuretic factor response.
150          Ventricular expression of mRNAs for atrial natriuretic factor, skeletal alpha-actin, and bet
151  However, in vivo imaging of a neuropeptide, atrial natriuretic factor, tagged with green fluorescent
152 iomyocytes suppresses cardiac troponin C and atrial natriuretic factor transcription.
153                  Moreover, the expression of atrial natriuretic factor, used as a molecular marker of
154                                              Atrial natriuretic factor-VEGF-B167 expression was low i
155                                              Atrial natriuretic factor was expressed in the TG ventri
156 cific markers desmin, sarcomeric myosin, and atrial natriuretic factor was similar to that of culture
157      Expression of fetal-type genes, such as atrial natriuretic factor, was also significantly lower
158 ing adult heart, steady-state mRNA levels of atrial natriuretic factor were increased in both the fet
159                                   Except for atrial natriuretic factor, which correlated weakly (r =
160                                              Atrial natriuretic factor, which signals via cGMP, also

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top